Metabolic Syndrome in a Population of In-Patients with Schizophrenia in the Western Siberia

Background. The relevance of this work is due to the incomplete nature of existing studies on risk factors of metabolic syndrome (MS) in patients with schizophrenia. Aim: to study the MS prevalence in schizophrenia in-patients and their clinical, therapeutic and socio-demographic features. Patients and methods: 517 in-patients diagnosed with schizophrenia according to the ICD-10 criteria were examined. All patients underwent a structured clinical interview (SCID); measurement of waist circumference, blood pressure and assessment of biochemical parameters for verification of MS based on the criteria of the IDF (International Diabetes Fediration). An assessment of the severity of clinical and psychopathological symptoms was performed using the PANSS. Results: the prevalence of MS in in-patients with schizophrenia in the Western Siberia is similar to that reported in the literature. It was found that in-patients with schizophrenia and MS are characterized by a predominance of women and older age, as well as a large proportion of divorced, and a smaller proportion of never married. Women with MS were older, got longer duration of illness, and got later onset of disease than men with MS. The age of disease onset was significantly greater in patients with MS than in patients without MS. Atypical antipsychotics were more often used as the basic antipsychotic treatment in the group of patients with MS but this difference between the groups did not reach statistical significance. Conclusions: the main risk factors in patients with schizophrenia and MS coincide with risk factors of MS in general population. A later onset of the disease can act as an independent risk factor. The relationship and mutual influence of risk factors for the development of MS in patients with schizophrenia needs further study.

1. Sugawara N, Yasui-Furukori N, Sato Y, Umeda T, Kishida I, Yamashita H, Saito M, Furukori H, Nakagami T, Hatakeyama M, Nakaji S, Kaneko S. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res. 2010;123(2–3):244–250. doi: 10.1016/j.schres.2010.08.030

2. Незнанов НГ, Мартынихин ИА, Танянский ДА, Ротарь ОП, Солнцев ВН, Соколян НА, Конради АО, Денисенко АД. Шизофрения — фактор, увеличивающий риск развития метаболического синдрома, результаты исследования с использованием метода подбора пар. Медицинский академический журнал. 2013;13(3):90–96. Neznanov NG, Martynihin IA, Tanyanskij DA, Rotar’ OP, Solncev VN, Sokolyan NA, Konradi AO, Denisenko AD. Schizophrenia is a factor that increases the risk of developing metabolic syndrome, the results of a study using the matching method. Medicinskij akademicheskij zhurnal. 2013;13(3):90– 96. (In Russ.).

3. Abou Kassm S, Hoertel N, Naja W, McMahon K, Barriere S, Blumenstock Y, Portefaix C, Raucher-Chene D, Bera-Potelle C, Cuervo-Lombard C, Guerin-Langlois C, Lemogne C, Peyre H, Kaladjian A, Limosin F. Metabolic syndrome among older adults with schizophrenia spectrum disorder: Prevalence and associated factors in a multicenter study. Psychiatry Res. 2019;275:238– 246. doi: 10.1016/j.psychres.2019.03.036

4. De Caluwe L, van Buitenen N, Gelan PJ. Prevalence of metabolic syndrome and its associated risk factors in an African-Caribbean population with severe mental illness. Psychiatry Res. 2019;281. https://doi.org/10.1016/j.psychres.2019.112558

5. Mamakou V, Thanopoulou A, Gonidakis F, Tentolouris N, Kontaxakis V. Schizophrenia and type 2 diabetes mellitus. Psychiatriki. 2018;29(1):64–73. doi: 10.22365/jpsych.2018.291.64

6. Fonseka TM, Muller DJ, Kennedy SH. Inammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications. Mol Neuropsychiatry. 2016;2(1):1–14. doi: 10.1159/000441521

7. Ijaz S, Bolea B, Davies S et al. Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry. 2018;18(1):275. Published 2018 Sep 3. doi:10.1186/s12888-018-1848-y

8. World Health Organization. The ICD-10 Classication of Mental and Behavioural Disorders — Diagnostic Criteria for Research. Geneva: WHO, 1993.

9. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation, 2006. https://idf.org/metabolic_syndrome, website of the International Diabetes Federation (accessed 07.08.2018).

10. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261 PMID: 3616518

11. Мосолов СН. Шкалы психометрической оценки симптоматики шизофрении и концепция позитивных и негативных расстройств. М.: Новый цвет, 2001. Mosolov SN. Scales of psychometric Assessment of symptoms of schizophrenia and the concept of positive and negative disorders. M.: Novyj cvet, 2001. (In Russ.).

12. Vancampfort D, Stubbs B, Mitchell AJ. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14:339–347. doi: 10.1002/wps.20252

13. Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome dened by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health. 2007;7:220. doi: 10.1186/1471-2458-7-220

14. Fang X, Wang Y, Chen Y, Ren J, Zhang C. Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics. Neuropsychiatr Dis Treat. 2019;15:2161– 2170. doi: 10.2147/NDT.S202159

15. Yazici MK, Anil Yağcioğlu AE, Ertuğrul A, Eni N, Karahan S, Karaağaoğlu E, Tokgözoğlu SL. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci. 2011;261(1):69–78. doi: 10.1007/s00406-010-0118-x

16. Bermudes RA, Keck PE Jr, Welge JA. The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders. Psychosomatics. 2006;47:491–497. doi: 10.1176/appi. psy.47.6.491

17. Fonseka TM, Muller DJ, Kennedy SH. Inflammatory Cytokines and Antipsychotic-Induced Weight Gain: Review and Clinical Implications. Mol Neuropsychiatry. 2016;2(1):1–14. doi: 10.1159/000441521

18. Abou-Setta AM, Mousavi SS, Spooner C et al. First-generation versus second-generation antipsychotics in adults: Comparative effectiveness. Rockville (MD): Agency for Healthcare Research and Quality (US); August, 2012.

19. Бибекова ЖБ, Стрельцов ЕА, Макарчук АС. Применение антипсихотиков длительного действия при шизофрении. Медицинский вестник Юга России. 2020;11(1):6–13. doi: 0.21886/2219-8075-2020-11-1-6-13 Bibekova ZhB, Strel’cov EA, Makarchuk AS. Application of antipsychotics of long-term action in schizophrenia. Medical Herald of the South of Russia. 2020;11(1):6–13. (In Russ.). doi: 0.21886/2219-8075-2020-11-1-6-13

20. Heald A, Livingston M, Yung A, de Hert MA. Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time. Hum Psychopharmacol. 2017;32(2):e2579. doi: 10.1002/hup.2579

21. Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin. Neurosci. 2018;20(1):63– 73. doi: 10.31887/DCNS.2018.20.1/bpenninx

22. McDonnell DP, Kryzhanovskaya LA, Zhao F, Detke HC, Feldman PD. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol. 2011;26(6):422–433. doi: 10.1002/hup.1225

23. Pucci G, Alcidi R, Tapc L, Battistaa F, Mattace-Rasoc F, Schillaci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: A review of the literature. Pharmacol Res. 2017;120:34–42. doi: 10.1016/j.phrs.2017.03.008

24. Баланова ЮА, Имаева АЭ, Куценко ВА, Капустина АВ, Муромцева ГА, Евстифеева СЕ, Максимов СА, Карамнова НС, Яровая ЕБ, Шальнова СА, Драпкина ОМ, Самохина ЮЮ, Редько АН, Алексеенко СН, Губарев СВ, Викторова ИА, Ливзан МА, Гришечкина ИА, Рожкова МЮ, Прищепа НН, Везикова НН, Скопец ИС, Якушин СС, Филиппов ЕВ, Добрынина НВ, Никулина НН, Переверзева КГ, Мосейчук КА. Метаболический синдром и его ассоциации с социально-демографическими и поведенческими факторами риска в российской популяции 25–64 лет. Кардиоваскулярная терапия и профилактика. 2020;19(4):45–57. doi: 10.15829/1728-8800-2020-2600 Balanova YuA, Imaeva AE, Kutsenko VA, Kapustina AV, Muromtseva GA, Evstifeeva SE, Maksimov SA, Karamnova NS, Yarovaya EB, Shalnova SA, Drapkina OM, Samokhina YuYu, Redko AN, Alekseenko SN, Gubarev SV, Viktorova IA, Livzan MA, Grishechkina IA, Rozhkova MYu, Prischepa NN, Vezikova NN, Skopec IS, Yakushin SS, Filippov EV, Dobrynina NV, Nikulina NN, Pereverzeva KG, Moseichuk KA. Metabolic syndrome and its associations with socio-demographic and behavioral risk factors in the russian population aged 25–64 years. Kardiovaskulyarnaya terapiya i profilaktika. 2020;19(4):45–57. (In Russ.). doi: 10.15829/1728-8800-2020-2600

25. Kornetova EG, Kornetov AN, Mednova IA, Dubrovskaya VV, Boiko AS, Bokhan NA, Loonen AJM, Ivanova SA. Changes in body fat and related biochemical parameters associated with atypical antipsychotic drug treatment in schizophrenia patients with or without metabolic syndrome. Front Psychiatry. 2019;10:803. doi: 10.3389/fpsyt.2019.00803